RT Journal Article
SR Electronic
T1 Updated Guidelines for the Management of Axial Disease in Psoriatic Arthritis
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 2286
OP 2289
DO 10.3899/jrheum.140877
VO 41
IS 11
A1 Peter Nash
A1 Ennio Lubrano
A1 Alberto Cauli
A1 William J. Taylor
A1 Ignazio Olivieri
A1 Dafna D. Gladman
YR 2014
UL http://www.jrheum.org/content/41/11/2286.abstract
AB Axial involvement in patients with psoriatic arthritis (PsA) remains common and can be defined in terms of spinal disease alone or in combination with peripheral manifestations. Diagnosis is based upon inflammatory spinal symptoms or the presence of radiological sacroiliitis and other radiographic signs of spondylitis, or by criteria for axial spondyloarthritis (SpA) defined by ASAS (Assessment of SpondyloArthritis International Society). Although recent data are scarce for efficacy of traditional therapies for axial disease (e.g., nonsteroidal antiinflammatory drugs, methotrexate, etc.), limited data are available for targeted biologics and novel agents. We identify and evaluate the efficacy of therapeutic interventions for treatment of axial disease in PsA. This review is an update of the axial PsA section of the treatment recommendations project by the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA).